EUVIMEDEUVIMED entdecken
Crossref

Delivery of CD47-SIRPα checkpoint blocker by BCMA-directed UCAR-T cells enhances antitumor efficacy in multiple myeloma

Qizhong Lu, Donghui Yang, Hexian Li, Zhixiong Zhu, Zongliang Zhang, Yongdong Chen, Nian Yang, Jia Li, Zeng Wang, Ting Niu, Aiping Tong

Cancer Letters · 2024-03 · 585 · 216660

DOI: 10.1016/j.canlet.2024.216660 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Letters, 2024-03. Verfasst von Qizhong Lu und 10 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Biotherapy and Cancer Center, Research Unit of Gene and Immunotherapy, Chinese Academy of Medical Sciences, Collaborative Inn…. Hauptthemen laut MEDLINE: Multiple Myeloma, Neoplasms. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 75 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In the treatment of relapsed or refractory multiple myeloma patients, BCMA-directed autologous CAR-T cells have showed excellent anti-tumor activity. However, their widespread application is limited due to the arguably cost and time-consuming. Multiple myeloma cells highly expressed CD47 molecule and interact with the SIRPα ligand on the surface of macrophages, in which evade the clearance of macrophages through the activation of "don't eat me" signal. In this study, a BCMA-directed universal CAR-T cells, BC404-UCART, secreting a CD47-SIRPα blocker was developed using CRISPR/Cas9 gene-editing system. BC404-UCART cells significantly inhibited tumor growth and prolonged the survival of mice in the xenograft model. The anti-tumor activity of BC404-UCART cells was achieved via two mechanisms, on the one hand, the UCAR-T cells directly killed tumor cells, on the other hand, the BC404-UCART cells enhanced the phagocytosis of macrophages by secreting anti-CD47 nanobody hu404-hfc fusion that blocked the "don't eat me" signal between macrophages and tumor cells, which provides a potential strategy for the development of novel "off-the-shelf" cellular immunotherapies for the treatment of multiple myeloma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaNeoplasmsHumansMiceAnimalsB-Cell Maturation AntigenCD47 AntigenReceptors, ImmunologicT-LymphocytesAntigens, DifferentiationPhagocytosis

Stichwörter der Autor:innen

Chimeric antigen receptorImmunotherapyMacrophagesMultiple myelomaNanobody

Substanzen

B-Cell Maturation AntigenCD47 AntigenReceptors, ImmunologicAntigens, DifferentiationCD47 protein, human

Autor:innen und Institutionen

  • State Key Laboratory of Biotherapy and Cancer Center, Research Unit of Gene and Immunotherapy, Chinese Academy of Medical Sciences, Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University,…
  • College of Veterinary Medicine, Shaanxi Center of Stem Cells Engineering and Technology, Northwest A&F University, Yangling, 712100, China.
  • Department of Hematology, State Key Laboratory of Biotherapy and Cancer Center, Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, China. Electronic address: niuting…

Zitieren

APA

Lu, Q., Yang, D., Li, H., Zhu, Z., Zhang, Z., Chen, Y., Yang, N., Li, J., Wang, Z., Niu, T., & Tong, A. (2024). Delivery of CD47-SIRPα checkpoint blocker by BCMA-directed UCAR-T cells enhances antitumor efficacy in multiple myeloma. Cancer Letters, 585, 216660. https://doi.org/10.1016/j.canlet.2024.216660

Vancouver

Lu Q, Yang D, Li H, Zhu Z, Zhang Z, Chen Y, et al. Delivery of CD47-SIRPα checkpoint blocker by BCMA-directed UCAR-T cells enhances antitumor efficacy in multiple myeloma. Cancer Letters. 2024;585:216660. doi:10.1016/j.canlet.2024.216660

BibTeX
@article{Lu2024,
  author = {Lu, Qizhong and Yang, Donghui and Li, Hexian and Zhu, Zhixiong and Zhang, Zongliang and Chen, Yongdong and Yang, Nian and Li, Jia and Wang, Zeng and Niu, Ting and Tong, Aiping},
  title = {Delivery of CD47-SIRPα checkpoint blocker by BCMA-directed UCAR-T cells enhances antitumor efficacy in multiple myeloma},
  journal = {Cancer Letters},
  year = {2024},
  volume = {585},
  pages = {216660},
  doi = {10.1016/j.canlet.2024.216660}
}
Kostenlos starten →